Literature DB >> 19341913

Design of recombinant hemoglobins for use in transfusion fluids.

Clara Fronticelli1, Raymond C Koehler.   

Abstract

Molecular biology has been applied to the development of hemoglobin-based oxygen carrier (HBOC) proteins that can be expressed in bacteria or yeast. The transformation of the hemoglobin molecule into an HBOC requires a variety of modifications for rendering the acellular molecule of hemoglobin physiologically acceptable when transfused in circulation. Hemoglobins with different oxygen affinities can be obtained by introducing mutations at the heme pocket, the site of oxygen binding, or by introducing surface mutations that stabilize the hemoglobin molecule in the low-oxygen-affinity state. Modification of the size of the heme pocket is also used to hinder nitric oxide depletion and associated vasoconstriction. Introduction of cysteine residues on the hemoglobin surface allows formation of intermolecular bonds and formation of polymeric HBOCs. These polymers of recombinant hemoglobin have the characteristics of molecular size, molecular stability, and oxygen delivery to hypoxic tissue suitable for an HBOC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19341913     DOI: 10.1016/j.ccc.2008.12.010

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  6 in total

Review 1.  Haemoglobin-based oxygen carriers: research and reality towards an alternative to blood transfusions.

Authors:  Andrea Mozzarelli; Luca Ronda; Serena Faggiano; Stefano Bettati; Stefano Bruno
Journal:  Blood Transfus       Date:  2010-06       Impact factor: 3.443

Review 2.  Development of recombinant hemoglobin-based oxygen carriers.

Authors:  Cornelius L Varnado; Todd L Mollan; Ivan Birukou; Bryan J Z Smith; Douglas P Henderson; John S Olson
Journal:  Antioxid Redox Signal       Date:  2012-11-16       Impact factor: 8.401

Review 3.  Exploring Oxidative Reactions in Hemoglobin Variants Using Mass Spectrometry: Lessons for Engineering Oxidatively Stable Oxygen Therapeutics.

Authors:  Michael Brad Strader; Abdu I Alayash
Journal:  Antioxid Redox Signal       Date:  2016-10-20       Impact factor: 8.401

4.  NO reactions with sol-gel and solution phase samples of the ferric nitrite derivative of HbA.

Authors:  Camille J Roche; Joel M Friedman
Journal:  Nitric Oxide       Date:  2009-11-15       Impact factor: 4.427

5.  Low affinity PEGylated hemoglobin from Trematomus bernacchii, a model for hemoglobin-based blood substitutes.

Authors:  Daniela Coppola; Stefano Bruno; Luca Ronda; Cristiano Viappiani; Stefania Abbruzzetti; Guido di Prisco; Cinzia Verde; Andrea Mozzarelli
Journal:  BMC Biochem       Date:  2011-12-20       Impact factor: 4.059

Review 6.  Artificial Blood Substitutes: First Steps on the Long Route to Clinical Utility.

Authors:  Samira Moradi; Ali Jahanian-Najafabadi; Mehryar Habibi Roudkenar
Journal:  Clin Med Insights Blood Disord       Date:  2016-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.